Dr. Keith Chan is a pharmaceutical scientist, a regulator, a professor, and an entrepreneur. He obtained his Ph.D. degree in Pharmaceutics from the University of Minnesota. He is currently Senior Advisor of Cornerstone IP Foundation and Adjunct Professor at the Graduate Institute of Intellectual Property and Technology Management, College of Commerce, National Chengchi University at Taiwan. He is also a Senior Partner at the Bright Spot Management Consultants Corp based on China, Hong Kong, and Taiwan. He is Senior Research Fellow at the Institute of International Intellectual Property at Beijing University Law School. He also serves as Director of International Affairs, GloboAsia LLC, Rockville, MD, USA and as advisors for several research institutes and regulatory agencies in Asia, as well as consultants for various pharmaceutical firms in Asia and in the US.
Dr. Chan worked for Ciba-Geigy Corporation (now Novartis) in Ardsley, New York for 15 years and held various senior and management positions. He published >150 abstracts/research articles in peer-reviewed journals and >200 professional presentations. He was elected fellow of the American Association of Pharmaceutical Scientists (AAPS) in 1995 for his scientific accomplishments on drug absorption in humans. He also worked for the US FDA as Division Director at the Office of Generic Drugs. In 1997, he co-foundered GloboMax LLC, a drug development organization, in Hanover, Maryland in 1997 and served as a consultant for numerous multi-national pharmaceutical and biotech firms in the US, Europe, and Asia. GloboMax was acquired by ICON, plc in 2003 and Dr. Chan exited from the operation. He served as Professor and Adjunct Professor at the School of Pharmacy, University of Maryland at Baltimore for many years and also served as Adjunct Professor and National Board of Advisor, College of Pharmacy, the University of Minnesota since 1984. He also taught in Asia including National Defense Medical Center, National Yang Ming University in Taiwan and Shang Yang Pharmaceutical University in China.
Over the last 15 years, he assisted various Asian companies, organized numerous workshops and conferences in China, Taiwan, Hong Kong, Singapore, and Korea. He lectured frequently in Asia in the hope of upgrading their pharmaceutical industry. He had success in assisting several Asian companies in their technology transfers and licensing. He also managed those new drug development projects starting from IND up to NDA. Some of those drug candidates have now marketed and launched in Japan, the United States, Asia, and Europe. His new adventure is joining a professional strategy consulting firm to provide various financial and investment networks to those technology companies to strengthen their financial structure that leads to products development or market expansion.